The public record for this applicant is narrow. The supplied filings contain one linked 510(k) record, K262478, and the collection's decision count is a single Substantially Equivalent outcome. That count describes the supplied filings as of the snapshot date, not the company's total portfolio, sales or safety history. The record identifies a Singapore-based applicant and a dental device reviewed by the Dental advisory committee. [1][2][6]
The documented device and its classification
K262478 covers the BCS Bioceramic Sealer. FDA's openFDA record lists the device name, product code KIF, regulation number 872.3820 and device class 2, with the openFDA device name given as Resin, Root Canal Filling and the medical specialty as Dental. The advisory committee is listed as DE, Dental, for both the reviewing committee and the advisory committee. [1][6]
The submission was a Traditional 510(k) with no third-party review, and the record notes a Summary rather than a Statement. No Predetermined Change Control Plan was authorized according to the premarket notification page. The regulation citation appears in the FDA record and in a third-party index of the same clearance. [1][2][6]
Dated submission and decision
FDA received the submission on July 20, 2026, and issued a Substantially Equivalent decision on October 16, 2026, under decision code SESE. The applicant is recorded as BCS Device Pte., Ltd., with a Singapore country code and a Singapore city and postal code in the filing address. That address is a filing address and is not treated here as a verified headquarters. [1][3][4]
The same K262478 entry appears in FDA 510(k) query results covering decision dates in October 2026, where it carries the same applicant name, device name, decision code and decision date. A third-party index lists the record as K262478, BCS Device Pte., Ltd., product code KIF, decision date October 16, 2026, Dental. [3][4][6]
What the collection shows, and what it does not
The supplied portfolio contains one linked record, a 510(k) with a SESE decision, and the sample of records is the same single entry. The decision count of one Substantially Equivalent outcome therefore describes the supplied filings only. It is not a measure of total company sales, total portfolio breadth or safety performance, and no recall records appear in the supplied sample. [1]
No parent company, brand owner, manufacturing site, customer list or commercial availability is verified in the public documents. The applicant name on the FDA record is the only legal entity identity documented here. Any relationship between the applicant and other entities using similar product names is not established by these filings. [1][6]
Product information published outside FDA records
A distributor page published by EndoTech Singapore describes the BCS BioCeramic Sealer as a bioceramic root canal sealer intended as a final sealing step, for professional dental use, and directs readers to the instructions for use for indications, contraindications, precautions and instructions. The page links to a brochure titled The BCS Bioactive Advantage and lists a legal entity, Endotech Innovation PTE.LTD. [7]
That page is a distributor's product description, not an FDA determination, and it does not establish efficacy, certification or clinical outcomes. Claims about the sealer's performance, its handling properties or its clinical role beyond the published description are not supported by the public documents and are left unstated. [7]

